Basal cell skin cancer, version 1.2016

Clinical practice guidelines in oncology

Christopher K. Bichakjian, Thomas Olencki, Sumaira Z. Aasi, Murad Alam, James S. Andersen, Daniel Berg, Glen M. Bowen, Richard T. Cheney, Gregory A. Daniels, L. Frank Glass, Roy C. Grekin, Kenneth Grossman, Susan A. Higgins, Alan L. Ho, Karl D. Lewis, Daniel D. Lydiatt, Kishwer S. Nehal, Paul Nghiem, Elise A. Olsen, Chrysalyne D. Schmults & 10 others Aleksandar D Sekulic, Ashok R. Shaha, Wade L. Thorstad, Malika Tuli, Marshall M. Urist, Timothy S. Wang, Sandra L. Wong, John A. Zic, Karin G. Hoffmann, Anita Engh

Research output: Contribution to journalArticle

40 Citations (Scopus)

Abstract

Basal cell carcinoma (BCC) of the skin is the most common cancer, with a higher incidence than all other malignancies combined. Although it is rare to metastasize, patients with multiple or frequently recurring BCC can suffer substantial comorbidity and be difficult to manage. Assessment of risk is a key element of management needed to inform treatment selection. The overall management of BCC primarily consists of surgical approaches, with radiation therapy as an alternate or adjuvant option. Many superficial therapies for BCC have been explored and continue to be developed, including topicals, cryosurgery, and photodynamic therapy. Two hedgehog pathway inhibitors were recently approved by the FDA for systemic treatment of advanced and metastatic BCC, and others are in development. The NCCN Guidelines for Basal Cell Skin Cancer, published in full herein, include recommendations for selecting among the various surgical approaches based on patient-, lesion-, and disease-specific factors, as well as guidance on when to use radiation therapy, superficial therapies, and hedgehog pathway inhibitors.

Original languageEnglish (US)
Pages (from-to)574-597
Number of pages24
JournalJNCCN Journal of the National Comprehensive Cancer Network
Volume14
Issue number5
StatePublished - May 1 2016

Fingerprint

Basal Cell Neoplasms
Basal Cell Carcinoma
Skin Neoplasms
Practice Guidelines
Radiotherapy
Cryosurgery
Photochemotherapy
Therapeutics
Comorbidity
Neoplasms
Guidelines
Skin
Incidence

ASJC Scopus subject areas

  • Oncology

Cite this

Bichakjian, C. K., Olencki, T., Aasi, S. Z., Alam, M., Andersen, J. S., Berg, D., ... Engh, A. (2016). Basal cell skin cancer, version 1.2016: Clinical practice guidelines in oncology. JNCCN Journal of the National Comprehensive Cancer Network, 14(5), 574-597.

Basal cell skin cancer, version 1.2016 : Clinical practice guidelines in oncology. / Bichakjian, Christopher K.; Olencki, Thomas; Aasi, Sumaira Z.; Alam, Murad; Andersen, James S.; Berg, Daniel; Bowen, Glen M.; Cheney, Richard T.; Daniels, Gregory A.; Glass, L. Frank; Grekin, Roy C.; Grossman, Kenneth; Higgins, Susan A.; Ho, Alan L.; Lewis, Karl D.; Lydiatt, Daniel D.; Nehal, Kishwer S.; Nghiem, Paul; Olsen, Elise A.; Schmults, Chrysalyne D.; Sekulic, Aleksandar D; Shaha, Ashok R.; Thorstad, Wade L.; Tuli, Malika; Urist, Marshall M.; Wang, Timothy S.; Wong, Sandra L.; Zic, John A.; Hoffmann, Karin G.; Engh, Anita.

In: JNCCN Journal of the National Comprehensive Cancer Network, Vol. 14, No. 5, 01.05.2016, p. 574-597.

Research output: Contribution to journalArticle

Bichakjian, CK, Olencki, T, Aasi, SZ, Alam, M, Andersen, JS, Berg, D, Bowen, GM, Cheney, RT, Daniels, GA, Glass, LF, Grekin, RC, Grossman, K, Higgins, SA, Ho, AL, Lewis, KD, Lydiatt, DD, Nehal, KS, Nghiem, P, Olsen, EA, Schmults, CD, Sekulic, AD, Shaha, AR, Thorstad, WL, Tuli, M, Urist, MM, Wang, TS, Wong, SL, Zic, JA, Hoffmann, KG & Engh, A 2016, 'Basal cell skin cancer, version 1.2016: Clinical practice guidelines in oncology', JNCCN Journal of the National Comprehensive Cancer Network, vol. 14, no. 5, pp. 574-597.
Bichakjian CK, Olencki T, Aasi SZ, Alam M, Andersen JS, Berg D et al. Basal cell skin cancer, version 1.2016: Clinical practice guidelines in oncology. JNCCN Journal of the National Comprehensive Cancer Network. 2016 May 1;14(5):574-597.
Bichakjian, Christopher K. ; Olencki, Thomas ; Aasi, Sumaira Z. ; Alam, Murad ; Andersen, James S. ; Berg, Daniel ; Bowen, Glen M. ; Cheney, Richard T. ; Daniels, Gregory A. ; Glass, L. Frank ; Grekin, Roy C. ; Grossman, Kenneth ; Higgins, Susan A. ; Ho, Alan L. ; Lewis, Karl D. ; Lydiatt, Daniel D. ; Nehal, Kishwer S. ; Nghiem, Paul ; Olsen, Elise A. ; Schmults, Chrysalyne D. ; Sekulic, Aleksandar D ; Shaha, Ashok R. ; Thorstad, Wade L. ; Tuli, Malika ; Urist, Marshall M. ; Wang, Timothy S. ; Wong, Sandra L. ; Zic, John A. ; Hoffmann, Karin G. ; Engh, Anita. / Basal cell skin cancer, version 1.2016 : Clinical practice guidelines in oncology. In: JNCCN Journal of the National Comprehensive Cancer Network. 2016 ; Vol. 14, No. 5. pp. 574-597.
@article{c8e74a4ff5164588aea536b7a4029af1,
title = "Basal cell skin cancer, version 1.2016: Clinical practice guidelines in oncology",
abstract = "Basal cell carcinoma (BCC) of the skin is the most common cancer, with a higher incidence than all other malignancies combined. Although it is rare to metastasize, patients with multiple or frequently recurring BCC can suffer substantial comorbidity and be difficult to manage. Assessment of risk is a key element of management needed to inform treatment selection. The overall management of BCC primarily consists of surgical approaches, with radiation therapy as an alternate or adjuvant option. Many superficial therapies for BCC have been explored and continue to be developed, including topicals, cryosurgery, and photodynamic therapy. Two hedgehog pathway inhibitors were recently approved by the FDA for systemic treatment of advanced and metastatic BCC, and others are in development. The NCCN Guidelines for Basal Cell Skin Cancer, published in full herein, include recommendations for selecting among the various surgical approaches based on patient-, lesion-, and disease-specific factors, as well as guidance on when to use radiation therapy, superficial therapies, and hedgehog pathway inhibitors.",
author = "Bichakjian, {Christopher K.} and Thomas Olencki and Aasi, {Sumaira Z.} and Murad Alam and Andersen, {James S.} and Daniel Berg and Bowen, {Glen M.} and Cheney, {Richard T.} and Daniels, {Gregory A.} and Glass, {L. Frank} and Grekin, {Roy C.} and Kenneth Grossman and Higgins, {Susan A.} and Ho, {Alan L.} and Lewis, {Karl D.} and Lydiatt, {Daniel D.} and Nehal, {Kishwer S.} and Paul Nghiem and Olsen, {Elise A.} and Schmults, {Chrysalyne D.} and Sekulic, {Aleksandar D} and Shaha, {Ashok R.} and Thorstad, {Wade L.} and Malika Tuli and Urist, {Marshall M.} and Wang, {Timothy S.} and Wong, {Sandra L.} and Zic, {John A.} and Hoffmann, {Karin G.} and Anita Engh",
year = "2016",
month = "5",
day = "1",
language = "English (US)",
volume = "14",
pages = "574--597",
journal = "JNCCN Journal of the National Comprehensive Cancer Network",
issn = "1540-1405",
publisher = "Cold Spring Publishing LLC",
number = "5",

}

TY - JOUR

T1 - Basal cell skin cancer, version 1.2016

T2 - Clinical practice guidelines in oncology

AU - Bichakjian, Christopher K.

AU - Olencki, Thomas

AU - Aasi, Sumaira Z.

AU - Alam, Murad

AU - Andersen, James S.

AU - Berg, Daniel

AU - Bowen, Glen M.

AU - Cheney, Richard T.

AU - Daniels, Gregory A.

AU - Glass, L. Frank

AU - Grekin, Roy C.

AU - Grossman, Kenneth

AU - Higgins, Susan A.

AU - Ho, Alan L.

AU - Lewis, Karl D.

AU - Lydiatt, Daniel D.

AU - Nehal, Kishwer S.

AU - Nghiem, Paul

AU - Olsen, Elise A.

AU - Schmults, Chrysalyne D.

AU - Sekulic, Aleksandar D

AU - Shaha, Ashok R.

AU - Thorstad, Wade L.

AU - Tuli, Malika

AU - Urist, Marshall M.

AU - Wang, Timothy S.

AU - Wong, Sandra L.

AU - Zic, John A.

AU - Hoffmann, Karin G.

AU - Engh, Anita

PY - 2016/5/1

Y1 - 2016/5/1

N2 - Basal cell carcinoma (BCC) of the skin is the most common cancer, with a higher incidence than all other malignancies combined. Although it is rare to metastasize, patients with multiple or frequently recurring BCC can suffer substantial comorbidity and be difficult to manage. Assessment of risk is a key element of management needed to inform treatment selection. The overall management of BCC primarily consists of surgical approaches, with radiation therapy as an alternate or adjuvant option. Many superficial therapies for BCC have been explored and continue to be developed, including topicals, cryosurgery, and photodynamic therapy. Two hedgehog pathway inhibitors were recently approved by the FDA for systemic treatment of advanced and metastatic BCC, and others are in development. The NCCN Guidelines for Basal Cell Skin Cancer, published in full herein, include recommendations for selecting among the various surgical approaches based on patient-, lesion-, and disease-specific factors, as well as guidance on when to use radiation therapy, superficial therapies, and hedgehog pathway inhibitors.

AB - Basal cell carcinoma (BCC) of the skin is the most common cancer, with a higher incidence than all other malignancies combined. Although it is rare to metastasize, patients with multiple or frequently recurring BCC can suffer substantial comorbidity and be difficult to manage. Assessment of risk is a key element of management needed to inform treatment selection. The overall management of BCC primarily consists of surgical approaches, with radiation therapy as an alternate or adjuvant option. Many superficial therapies for BCC have been explored and continue to be developed, including topicals, cryosurgery, and photodynamic therapy. Two hedgehog pathway inhibitors were recently approved by the FDA for systemic treatment of advanced and metastatic BCC, and others are in development. The NCCN Guidelines for Basal Cell Skin Cancer, published in full herein, include recommendations for selecting among the various surgical approaches based on patient-, lesion-, and disease-specific factors, as well as guidance on when to use radiation therapy, superficial therapies, and hedgehog pathway inhibitors.

UR - http://www.scopus.com/inward/record.url?scp=84968747355&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84968747355&partnerID=8YFLogxK

M3 - Article

VL - 14

SP - 574

EP - 597

JO - JNCCN Journal of the National Comprehensive Cancer Network

JF - JNCCN Journal of the National Comprehensive Cancer Network

SN - 1540-1405

IS - 5

ER -